Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • lacosamide

    - PMLiVE

    AstraZeneca’s Enhertu combination approved by FDA for HER2-positive breast cancer

    Around one in five breast cancer cases are HER2-positive

    - PMLiVE

    UCB’s Fintepla shows positives results for Lennox-Gastaut syndrome

    The study demonstrated a sustained reduction in seizures for patients

    Epilepsy meds app silver award at PMi Awards

    Genetic Digital Wins Silver at PM Society Digital Awards for Epilepsy Meds Clinical Support App

    Genetic Digital wins Silver at the PM Society Digital Awards for Epilepsy Meds, a clinical support app developed with Desitin and ChangeMed to aid patient-specific prescribing in epilepsy care.

    Genetic Digital

    market access in Japan

    Implementation of Cost-Effectiveness Analysis in Japan’s Health Technology Assessment Process

    Japan’s evolving approach to market access includes a formal cost-effectiveness analysis (CEA) requirement for certain new medicines and medical devices. Introduced as part of a broader health technology assessment (HTA)...

    Petauri Evidence

    Genetic Digital has been shortlisted for a PM Society Digital Award for Epilepsy Meds.

    Genetic Digital Shortlisted for PM Society Digital Award for Epilepsy Meds App

    Genetic Digital has been shortlisted for a PM Society Digital Award for Epilepsy Meds, a mobile-first app that helps healthcare professionals make safer, patient-specific prescribing decisions in epilepsy care. The...

    Genetic Digital

    - PMLiVE

    UCB shares promising results for fenfluramine in ultra-rare form of epilepsy

    CDKL5 deficiency disorder occurs in approximately one in 40,000 to 60,000 live births

    - PMLiVE

    AstraZeneca/Daiichi Sankyo’s Datroway granted FDA accelerated approval for lung cancer

    Approximately 226,650 new cases of lung cancer will be diagnosed in the US this year

    - PMLiVE

    UCB’s Bimzelx demonstrates lasting efficacy in phase 3 psoriatic arthritis trials

    Approximately 125 million people worldwide are affected by some form of psoriasis

    - PMLiVE

    AstraZeneca/Daiichi Sankyo share positive phase 3 results for Enhertu in early breast cancer

    Around one in three patients with early-stage breast cancer are considered high risk

    - PMLiVE

    AstraZeneca/Daiichi Sankyo’s Enhertu shows promise in first-line HER2-positive breast cancer

    Up to 20% of patients with metastatic breast cancer are affected by HER2-positive disease

    - PMLiVE

    AstraZeneca/Daiichi Sankyo’s Datroway approved by EC to treat breast cancer

    Approximately 557,000 people are diagnosed with breast cancer every year in Europe

    - PMLiVE

    AstraZeneca/Daiichi Sankyo’s Enhertu receives EC approval for HER2-low breast cancer

    Approximately 557,000 people are diagnosed with breast cancer every year in Europe

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links